FORMULATION AND OPTIMIZATION AND IN VITRO CHARACTERIZATION OF OLANZAPINE LIPOSOME
DOI:
https://doi.org/10.22159/ijap.2021v13i5.42085Keywords:
Design expert, Entrapment efficiency, Lipid film hydration, Liposomes, SchizophreniaAbstract
Objective: Olanzapine (OZ) is a thioeno benzodiazepine class second-generation or atypical antipsychotic that selectively binds to central dopamine D2 and serotonin (5-HT2c) receptors used for the treatment of schizophrenia and bipolar disorder. The present paper is aimed at developing an optimized liposome-loaded OZ as an approach for brain targeting through the nasal route for effective therapeutic management of schizophrenia.
Methods: The OZ liposomes were prepared by the thin-film hydration method. Various independent variable such as phospholipid, cholesterol and sonication time was optimized by using Design-Expert® Software to obtain the dependent variables of entrapment efficiency, vesicle size and zeta potential. The optimized formulation was predicted based on the response obtained by the point prediction method.
Results: The entrapment efficiency of the formulation was range between 72.9 and 85.1 %. The average particle size of all the 15 experimental runs lies between the minimum and maximum values of the size 258.33 to 325.32 nm, respectively. The zeta potential ranges from-27.53 to-11.46 mV. The optimized formulation for characterized for its morphology by Transmission Electron Microscopy (TEM). In vitro release studies of OZ-loaded liposomal formulation was carried by dialysis sac method using pH 7.4 phosphate buffer (PBS) as a medium. The maximum release was found to be 98.43±1.2 % up to 24 h. The R2 zero-order kinetics and Korsmeyer-Peppas model was found to be 0.9919 and 0.9664, respectively. The zero-order shows the best-fit model with a highest R2 value exhibiting better correlation and the ‘n’ value was also found to be 0.85; indicating both diffusion-controlled and swelling-controlled drug release that is anomalous transport.
Conclusion: The results, clearly states that the prepared formulations justify the parameters and OZ might be a suitable candidate to target the brain through nasal delivery.
Downloads
References
Gaebel W, Zielasek J. Schizophrenia in 2020: trends in diagnosis and therapy. Psychiatry Clin Neurosci 2015;69:661-73.
Valencia M, Fresan A, Juarez F, Escamilla R, Saracco R. The beneficial effects of combining pharmacological and psychosocial treatment on remission and functional outcome in outpatients with schizophrenia. J Psychiatr Res 2013;47:1886–92.
Howard P, Twycross R, Shuster J, Mihalyo M, Wilcock A. Antipsychotics. J Pain Symptom Manag 2011;41:956–65.
Larsen JM, Martin DR, Byrne ME. Recent advances in delivery through the blood-brain barrier. Curr Top Med Chem 2014;14:1148–60.
Silva AC, Gonzalez Mira E, Sousa Lobo JM, Amaral MH. Current progresses on nano delivery systems for the treatment of neuropsychiatric diseases: alzheimer's and schizophrenia. Curr Pharm Des 2013;19:7185–95.
Yogesh S Thorat, Nagesh S Kote, Virendra V Patil, Avinash H Hosmani. Formulation and evaluation of liposomal gel containing extract of piprine. Int J Curr Pharm Res 2020;12:126-9.
Mittal D, Ali A, Md S, Baboota S, Sahni JK, Ali J. Insights into the direct nose to brain delivery: current status and future perspective. Drug Delivery 2014;21:75–86.
Kozlovskaya L, Abou Kaoud M, Stepensky D. Quantitative analysis of drug delivery to the brain via nasal route. J Controlled Release 2014;189:133–40.
Leonor Pinzon Daza M, Campia I, Kopecka J, Garzon R, Ghigo D, Riganti C. Nanoparticle-and liposome-carried drugs: new strategies for active targeting and drug delivery across blood-brain barrier. Curr Drug Metab 2013;14:625–40.
Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomaterialia 2011;7:4169-76.
Jafari S, Bouillon ME, Huang XF, Pyne SG, Fernandez Enright F. Novel olanzapine analogues presenting a reduced H1 receptor affinity and retained 5HT2A/D2 binding affinity ratio. BMC Pharmacol 2012;12:1-8.
Srivastava S, Ketter TA. Clinical relevance of treatments for acute bipolar disorder: balancing therapeutic and adverse effects. Clin Ther 2011;33:B40-48.
Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 2003;63:493-512.
Rahul Tiwaria, Kaliyaperumal Viswanathanb, Suresh Prasad Vyasa, Vandana Soni. In vitro evaluation of lectinized cisplatin bearing liposomes system. Int J Appl Pharm 2020;12:60-4.
Reema Narayan, Mohan Singh, Om Prakash Ranjan, Yogendra Nayak, Sanjay Garg, Gopal V Shavi, et al. Development of risperidone liposomes for brain targeting through intranasal route. Life Sci 2016;163:38–45.
Ajay Kumar, Shital Badde, Ravindra Kamble, Varsha B Pokharkar. Development and characterization of liposomal drug delivery system for nimesulide. Int J Pharm Pharm Sci 2010;2:87-9.
Ramkanth S, Anitha P, Gayathri R, Mohan S, Dinesh Babu. Formulation and design optimization of nano-transferosomes using pioglitazone and eprosartan mesylate for concomitant therapy against diabetes and hypertension. Eur J Pharm Sci 2021;162:105811.
Rompicharla S, Bhatt H, Shah A, Komanduri N, Vijayasarathy D, Ghosh B, et al. Formulation optimization, characterization, and evaluation of in vitro cytotoxic potential of curcumin loaded solid lipid nanoparticles for improved anticancer activity. Chem Phys Lipids 2017;208:10–8.
Girish Sailor, Seth AK, Ghanshyam Parmar, Sachin Chauhan, Ankur Javia. Formulation and in vitro evaluation of berberine-containing liposome optimized by 32 full factorial designs. J Appl Pharm Sci 2015;5:23-8.
Tefas LR, Muntean DM, Vlase L. Quercetin-loaded liposomes: formulation optimization through a D-optimal experimental design. Farmacia 2015;63:26-33.
Colletier JP, Chaize B, Winterhalter M. Protein encapsulation in liposomes: efficiency depends on interactions between protein and phospholipid bilayer. BMC Biotechnol 2002;2:9.
Jaafar Maalej C, Diab R, Andrieu V. Ethanol injection method for hydrophilic and lipophilic drug-loaded liposome preparation. J Liposome Res 2010;20:228-43.
Chavan SS, Ingle SG, Vavia PR. Preparation and characterization of solid lipid nanoparticle-based nasal spray of budesonide. Drug Delivery Transl Res 2013;3:402–8.
Nagayasu V, Uchiyama K, Kiwada H. The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv Drug Delivery Rev 1999;40:75-87.
Garg A, Bhalala K, Tomar DS. In-situ single pass intestinal permeability and pharmacokinetic study of developed lumefantrine loaded solid lipid nanoparticles. Int J Pharm 2017;516:120-30.
Junyaprasert VB, Teeranachaideekul V, Supaperm T. Effect of charged and non-ionic membrane additives on physicochemical properties and stability of niosomes. AAPS PharmSciTech 2008;9:851–9.
Vakili Ghartavol R, Rezayat SM, Faridi Majidi R. Optimization of docetaxel loading conditions in liposomes: proposing potential products for metastatic breast carcinoma chemotherapy. Sci Rep 2020;10:5569.
Vali AM, Toliyat T, Shafaghi B, Dadashzadeh S. Preparation, optimization, and characterization of topotecan loaded PEGylated liposomes using factorial design. Drug Dev Ind Pharm 2008;34:10–23.
Shabnam, Prathima Srinivas, Ravindra Babu DS. Formulation and evaluation of parenteral methotrexate nanoliposomes. Int J Pharm Pharm Sci 2014;11:295-300.
Bhavin K Patel, Rajesh H Parikh. Formulation development and evaluation of temozolomide loaded hydrogenated soya phosphatidylcholine liposomes for the treatment of brain cancer. Asian J Pharm Clin Res 2016;9:240-3.
Published
How to Cite
Issue
Section
Copyright (c) 2021 G. NETHRA VANI, M. ALAGUSUNDARAM, K. B. CHANDRASEKAR
This work is licensed under a Creative Commons Attribution 4.0 International License.
